Metabolomic profiling to improve glomerular filtration rate estimation

a proof-of-concept study

Josef Coresh, Lesley A. Inker, Yingying Sang, Jingsha Chen, Tariq Shafi, Wendy S Post, Michael G. Shlipak, Lisa Ford, Kelli Goodman, Regis Perichon, Tom Greene, Andrew S. Levey

Research output: Contribution to journalArticle

Abstract

BACKGROUND: Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS: We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30% of mGFR (1-P30), before and after bias correction. RESULTS: Of untargeted metabolites in the AASK and MESA, 283 of 780 (36%) and 387 of 1447 (27%), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9%, respectively) than eGFRcr [11.2 and 18.5%, respectively (P < 0.001 for both)] and estimating GFR using cystatin C (eGFRcys) [10.6% (P = 0.02) and 9.1% (P < 0.05), respectively] but was not consistently better than eGFR using both creatinine and cystatin C [3.7% (P > 0.05) and 9.1% (P < 0.05), respectively]. A panel excluding creatinine and demographics still performed well [1-P30 6.4% (P = 0.11) and 3.4% (P < 0.001) in the AASK and MESA] versus eGFRcr. CONCLUSIONS: Multimetabolite panels can enable accurate GFR estimation. Metabolomic equations, preferably excluding creatinine and demographic characteristics, should be tested for robustness and generalizability as a potential confirmatory test when eGFRcr is unreliable.

Original languageEnglish (US)
Pages (from-to)825-833
Number of pages9
JournalNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
Volume34
Issue number5
DOIs
StatePublished - May 1 2019

Fingerprint

Metabolomics
Glomerular Filtration Rate
Creatinine
Atherosclerosis
Demography
Cystatin C
Kidney Diseases
Chronic Renal Insufficiency
Liquid Chromatography
African Americans
Gas Chromatography-Mass Spectrometry
Mass Spectrometry
Epidemiology
Cross-Sectional Studies
Hypertension

Keywords

  • creatinine
  • estimating equations
  • GFR
  • kidney function
  • metabolomics

ASJC Scopus subject areas

  • Nephrology
  • Transplantation

Cite this

Metabolomic profiling to improve glomerular filtration rate estimation : a proof-of-concept study. / Coresh, Josef; Inker, Lesley A.; Sang, Yingying; Chen, Jingsha; Shafi, Tariq; Post, Wendy S; Shlipak, Michael G.; Ford, Lisa; Goodman, Kelli; Perichon, Regis; Greene, Tom; Levey, Andrew S.

In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, Vol. 34, No. 5, 01.05.2019, p. 825-833.

Research output: Contribution to journalArticle

Coresh, Josef ; Inker, Lesley A. ; Sang, Yingying ; Chen, Jingsha ; Shafi, Tariq ; Post, Wendy S ; Shlipak, Michael G. ; Ford, Lisa ; Goodman, Kelli ; Perichon, Regis ; Greene, Tom ; Levey, Andrew S. / Metabolomic profiling to improve glomerular filtration rate estimation : a proof-of-concept study. In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 2019 ; Vol. 34, No. 5. pp. 825-833.
@article{ca6fbc30d2ec45f798a77af8efb779bf,
title = "Metabolomic profiling to improve glomerular filtration rate estimation: a proof-of-concept study",
abstract = "BACKGROUND: Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS: We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30{\%} of mGFR (1-P30), before and after bias correction. RESULTS: Of untargeted metabolites in the AASK and MESA, 283 of 780 (36{\%}) and 387 of 1447 (27{\%}), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9{\%}, respectively) than eGFRcr [11.2 and 18.5{\%}, respectively (P < 0.001 for both)] and estimating GFR using cystatin C (eGFRcys) [10.6{\%} (P = 0.02) and 9.1{\%} (P < 0.05), respectively] but was not consistently better than eGFR using both creatinine and cystatin C [3.7{\%} (P > 0.05) and 9.1{\%} (P < 0.05), respectively]. A panel excluding creatinine and demographics still performed well [1-P30 6.4{\%} (P = 0.11) and 3.4{\%} (P < 0.001) in the AASK and MESA] versus eGFRcr. CONCLUSIONS: Multimetabolite panels can enable accurate GFR estimation. Metabolomic equations, preferably excluding creatinine and demographic characteristics, should be tested for robustness and generalizability as a potential confirmatory test when eGFRcr is unreliable.",
keywords = "creatinine, estimating equations, GFR, kidney function, metabolomics",
author = "Josef Coresh and Inker, {Lesley A.} and Yingying Sang and Jingsha Chen and Tariq Shafi and Post, {Wendy S} and Shlipak, {Michael G.} and Lisa Ford and Kelli Goodman and Regis Perichon and Tom Greene and Levey, {Andrew S.}",
year = "2019",
month = "5",
day = "1",
doi = "10.1093/ndt/gfy094",
language = "English (US)",
volume = "34",
pages = "825--833",
journal = "Nephrology Dialysis Transplantation",
issn = "0931-0509",
publisher = "Oxford University Press",
number = "5",

}

TY - JOUR

T1 - Metabolomic profiling to improve glomerular filtration rate estimation

T2 - a proof-of-concept study

AU - Coresh, Josef

AU - Inker, Lesley A.

AU - Sang, Yingying

AU - Chen, Jingsha

AU - Shafi, Tariq

AU - Post, Wendy S

AU - Shlipak, Michael G.

AU - Ford, Lisa

AU - Goodman, Kelli

AU - Perichon, Regis

AU - Greene, Tom

AU - Levey, Andrew S.

PY - 2019/5/1

Y1 - 2019/5/1

N2 - BACKGROUND: Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS: We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30% of mGFR (1-P30), before and after bias correction. RESULTS: Of untargeted metabolites in the AASK and MESA, 283 of 780 (36%) and 387 of 1447 (27%), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9%, respectively) than eGFRcr [11.2 and 18.5%, respectively (P < 0.001 for both)] and estimating GFR using cystatin C (eGFRcys) [10.6% (P = 0.02) and 9.1% (P < 0.05), respectively] but was not consistently better than eGFR using both creatinine and cystatin C [3.7% (P > 0.05) and 9.1% (P < 0.05), respectively]. A panel excluding creatinine and demographics still performed well [1-P30 6.4% (P = 0.11) and 3.4% (P < 0.001) in the AASK and MESA] versus eGFRcr. CONCLUSIONS: Multimetabolite panels can enable accurate GFR estimation. Metabolomic equations, preferably excluding creatinine and demographic characteristics, should be tested for robustness and generalizability as a potential confirmatory test when eGFRcr is unreliable.

AB - BACKGROUND: Estimation of glomerular filtration rate (GFR) using estimated glomerular filtration rate creatinine (eGFRcr) is central to clinical practice but has limitations. We tested the hypothesis that serum metabolomic profiling can identify novel markers that in combination can provide more accurate GFR estimates. METHODS: We performed a cross-sectional study of 200 African American Study of Kidney Disease and Hypertension (AASK) and 265 Multi-Ethnic Study of Atherosclerosis (MESA) participants with measured GFR (mGFR). Untargeted gas chromatography/dual mass spectrometry- and liquid chromatography/dual mass spectrometry-based quantification was followed by the development of targeted assays for 15 metabolites. On the log scale, GFR was estimated from single- and multiple-metabolite panels and compared with eGFR using the Chronic Kidney Disease Epidemiology equations with creatinine and/or cystatin C using established metrics, including the proportion of errors >30% of mGFR (1-P30), before and after bias correction. RESULTS: Of untargeted metabolites in the AASK and MESA, 283 of 780 (36%) and 387 of 1447 (27%), respectively, were significantly correlated (P ≤ 0.001) with mGFR. A targeted metabolite panel eGFR developed in the AASK and validated in the MESA was more accurate (1-P30 3.7 and 1.9%, respectively) than eGFRcr [11.2 and 18.5%, respectively (P < 0.001 for both)] and estimating GFR using cystatin C (eGFRcys) [10.6% (P = 0.02) and 9.1% (P < 0.05), respectively] but was not consistently better than eGFR using both creatinine and cystatin C [3.7% (P > 0.05) and 9.1% (P < 0.05), respectively]. A panel excluding creatinine and demographics still performed well [1-P30 6.4% (P = 0.11) and 3.4% (P < 0.001) in the AASK and MESA] versus eGFRcr. CONCLUSIONS: Multimetabolite panels can enable accurate GFR estimation. Metabolomic equations, preferably excluding creatinine and demographic characteristics, should be tested for robustness and generalizability as a potential confirmatory test when eGFRcr is unreliable.

KW - creatinine

KW - estimating equations

KW - GFR

KW - kidney function

KW - metabolomics

UR - http://www.scopus.com/inward/record.url?scp=85047983485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047983485&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfy094

DO - 10.1093/ndt/gfy094

M3 - Article

VL - 34

SP - 825

EP - 833

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

SN - 0931-0509

IS - 5

ER -